Photo of Bishal Gyawali from oncology.queensu.ca
Oct 7, 2023, 18:27
Bishal Gyawali: This offers a good lesson on why oncology KOLs are not always the best person to interpret the results of a trial.
Quoting Bishal Gyawali, Associate Professor at Queen’s University, on LinkedIn:
“This is from FDA’s ODAC document re Codebreak 200 trial. This offers a good lesson on why oncology KOLs are not always the best person to interpret the results of a trial. Stop blindly following the KOLs or the guidelines and start thinking critically. When codebreak 200 results were published, some KOLs said sotorasib has now become the standard of care and that it beat docetaxel hands down. I had documented flaws with this trial back in April.”
Source: Bishal Gyawali/LinkedIn.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33